3rd Quarter - Report

HOLLAND & KNIGHT LLP for ALLIANCE FOR REGENERATIVE MEDICINE

Period 3rd Quarter 2011 Filed Oct 11, 2011 Signed by Richard M. Gold, Partner

Official filing
Firm
HOLLAND & KNIGHT LLP
Client
ALLIANCE FOR REGENERATIVE MEDICINE
Income
$80,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.

LobbyistCovered position, as disclosed
LISA A BARKOVIC —
LINDSAY BRITT —
PAOLO MASTRANGELO —
ANDREW SCHOLNICK —
MICHAEL WERNER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Natl Institute of Standards & Technology (NIST)

Bills named: H.R. 1862 (112th)

Budget/Appropriations BUD

Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards for regenerative medicine.

LobbyistCovered position, as disclosed
LISA A BARKOVIC —
LINDSAY BRITT —
PAOLO MASTRANGELO —
ANDREW SCHOLNICK —
MICHAEL WERNER —

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institute of Standards & Technology (NIST)

Medical/Disease Research/Clinical Labs MED

Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.

LobbyistCovered position, as disclosed
LISA A BARKOVIC —
LINDSAY BRITT —
PAOLO MASTRANGELO —
ANDREW SCHOLNICK —
MICHAEL WERNER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institute of Standards & Technology (NIST); Natl Institutes of Health (NIH); Food & Drug Administration (FDA)

Bills named: H.R. 1862 (112th)

Science/Technology SCI

Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.

LobbyistCovered position, as disclosed
LISA A BARKOVIC —
LINDSAY BRITT —
PAOLO MASTRANGELO —
ANDREW SCHOLNICK —
MICHAEL WERNER —

Contacted: Food & Drug Administration (FDA); Natl Institutes of Health (NIH); SENATE; Natl Institute of Standards & Technology (NIST); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.